Published Date: 19 Apr 2023
More melanoma patients were kept in remission with the combination of a personalized cancer vaccine and the popular drug Keytruda than with the immune therapy alone, according to co-developers Moderna Inc. Merck & Co., too. said in their initial, thorough presentation.
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation